Previous 10 | Next 10 |
TEL AVIV, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), announced that Dr. Dror Harats, CEO will deliver a company presentation today at the 2019 BIO International Convention in Philadelphia. The presentation will include a discussion on the rec...
DelMar Pharmaceuticals (NASDAQ: DMPI ) -41% on equity offering . More news on: DelMar Pharmaceuticals, Inc., Vascular Biogenics Ltd., Centene Corporation, Stocks on the move, Read more ...
VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose (498 days vs. 172.5 days, p=0.03) CA-125 response (GCIG) was reported in 58% of evaluable patients and was predictive of overall survival, in patients treated with a therapeutic dose...
TEL AVIV, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that MRI data from VB-111 Phase 2 and Phase 3 studies in recurrent GBM (rGBM), presented yesterday at the 2019 American Society of Clinical Oncology (ASCO) annual meeting, showed a survival ...
TEL AVIV, Israel, May 23, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announced the upcoming presentation of final results from the Phase 2 study of VB-111 in ovarian cancer at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, to be held May 31 - ...
Vascular Biogenics Ltd. (NASDAQ:VBLT) Q1 2019 Earnings Conference Call May 15, 2019 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dror Harats - Chief Executive Officer Amos Ron - Chief Financial Officer Conference Call Participants Soumit Roy - Jones Tra...
VBL Therapeutics (NASDAQ: VBLT ): Q1 GAAP EPS of -$0.12 misses by $0.06 . More news on: Vascular Biogenics Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel, May 15, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2019, and provided a corporate update. “As we continue to advance development of VB-111, we are getting a better understanding...
TEL AVIV, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio ...
Vascular Biogenics Ltd. (VBLT) Q4 2018 Results Conference Call March 28, 2019 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dror Harats - CEO Amos Ron - CFO Erez Feige - VP of Business Operations Conference Call Participants Swayampakula Ramakanth - H.C...
News, Short Squeeze, Breakout and More Instantly...
Vascular Biogenics Ltd. Company Name:
VBLT Stock Symbol:
NASDAQ Market:
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GL...
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annua...
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today ann...